| Literature DB >> 33954257 |
Maria Araceli Diaz Cruz1, Dan Lund2, Ferenc Szekeres3, Sandra Karlsson2, Maria Faresjö2, Dennis Larsson4.
Abstract
Nuclear receptors (NRs) are ligand-activated transcription factors that regulate gene expression when bound to specific DNA sequences. Crosstalk between steroid NR systems has been studied for understanding the development of hormone-driven cancers but not to an extent at a genetic level. This study aimed to investigate crosstalk between steroid NRs in conserved intron and exon sequences, with a focus on steroid NRs involved in prostate cancer etiology. For this purpose, we evaluated conserved intron and exon sequences among all 49 members of the NR Superfamily (NRS) and their relevance as regulatory sequences and NR-binding sequences. Sequence conservation was found to be higher in the first intron (35%), when compared with downstream introns. Seventy-nine percent of the conserved regions in the NRS contained putative transcription factor binding sites (TFBS) and a large fraction of these sequences contained splicing sites (SS). Analysis of transcription factors binding to putative intronic and exonic TFBS revealed that 5 and 16%, respectively, were NRs. The present study suggests crosstalk between steroid NRs, e.g., vitamin D, estrogen, progesterone, and retinoic acid endocrine systems, through cis-regulatory elements in conserved sequences of introns and exons. This investigation gives evidence for crosstalk between steroid hormones and contributes to novel targets for steroid NR regulation.Entities:
Keywords: conserved sequences; crosstalk; nuclear receptor binding domains; splicing sites; transcription factor binding sites
Year: 2021 PMID: 33954257 PMCID: PMC8051167 DOI: 10.1515/med-2021-0264
Source DB: PubMed Journal: Open Med (Wars)
Figure 1Percentage of sequence conservation for each intron group (1st to 9th) from 25 genes generated from the NRS analysis. Mann–Whitney U statistical test was performed to assess the differences of conserved sequences between different groups of introns (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Frequency distribution of the conserved patterns identified as TFBS for the introns 1–9
| Intron | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Cons patterns | 385 | 147 | 173 | 88 | 121 | 84 | 20 | 8 | 18 | 1,044 |
| TFBS | 294 | 121 | 150 | 67 | 96 | 63 | 14 | 3 | 16 | 824 |
| SS | 137 | 41 | 58 | 28 | 42 | 30 | 6 | 4 | 5 | 351 |
| TFBS/Cons patterns (%) | 76 | 82 | 87 | 76 | 79 | 75 | 70 | 38 | 89 | |
| SS/Cons Patterns (%) | 36 | 28 | 34 | 32 | 35 | 36 | 30 | 50 | 28 |
*Cons patterns, conserved patterns; TFBS, Transcription factor binding sites identified in the conserved patterns; SS, Splicing sites identified in the conserved patterns; % TFBS/Cons patterns, percentage of TFBS with respect to the total number of conserved patterns; % SS/Cons patterns, percentage of SS with respect to the total number of conserved patterns.
Figure 2Frequency distribution of conserved pattern groups in intron 1–9 for the 25 analyzed genes. Conserved patterns were classified into four different groups: TFBS, TFBS-SS, SS, and not identified. The TFBS-SS group contained patterns that were identified as both TFBS and SS. Intron 8 is excluded due to the low number of conserved patterns shown in this intron (n = 8). Frequency distribution of the four groups (TFBS, TFBS-SS, SS, and Not identified) among introns was analyzed with Chi-square test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
Figure 3Distribution of the identified TFBDs for the analyzed TFBS, among the ten most numerous domain family types: Homeodomain, Forkhead, Homeodomain POU, C2H2 ZF, bZIP, Nuclear receptor, bHLH, Ets, Sox, and GATA. Intron 8 is excluded due to the low number of conserved patterns shown in this intron (n = 8).
Nuclear receptor-binding domains detected in the intronic conserved sequences of three NR genes involved in prostate cancer etiology
| Gene | Location | Nuclear receptor |
|---|---|---|
| VDR | Intron 3 | NR2F6, NR2F1, NR2F2, HNF4A, HNF4G |
| AR | Intron 1 | ESR1, ESR2, PGR, AR, NR2E1, RXRA, RXRB, RXRG, NR3C1, NR3C2, NR2E3, NR4A1, NR4A2, NR4A3, ESRRB |
| Intron 3 | NR4A1, NR4A2, NR4A3, HNF4A, HNF4G, RORA, RORB, RORC, NR2E1 | |
| Intron 5 | VDR, ESR1, ESR2, PGR, AR, HNF4A, HNF4G, NR1H4, NR1H3, NR3C1, NR3C2 | |
| Intron 7 | VDR, PGR, AR, NR3C1, NR3C2 | |
| RXRA | Intron 1 | RARB, RARA, RARG |
Nuclear receptor-binding domains detected in the exonic conserved sequences of three NR genes involved in prostate cancer etiology
| Gene | Location | Nuclear receptor |
|---|---|---|
| VDR | Exon 4 | PPARD |
| Exon 7 | RORA, RORB, RORC, RARA, RARB, NR1D1, NR1D2, NR2F1 NR2F2, NR2F6, PPARA, NR2C2 | |
| AR | Exon 4 | VDR, ESR1, ESR2, NR1H2, NR1H3, NR1H4, RORA, RORB, RORC, RARA, RARB, RARG, NR2C1, NR2C2, RXRA, RXRB, RXRG, NR2F1, NR2F2, NR2F6, HNF4A, HNF4G, NR2E1, PPARA, PPARD, PPARG, NR5A2, NR4A1, NR5A1, NR6A1, NR4A3, THRA, THRB, NR1D1, NR1D2 |
| Exon 7 | ESR1, ESR2, NR1H2, NR1H3, RARB, PPARA, PPARG, PPARD, NR5A2, NR2C1, NR2C2, NR4A1, NR6A1, NR1D1, NR1D2, RARA, RARG, RORA, RORB, RORC, NR4A2, NR4A3, RXRA, RXRB, RXRG, NR2F1, NR2F2, NR2F6 | |
| RXRA | Exon 4 | RORA, RORB, RORC, RARA, RARB, RARG, RXRA, RXRB, RXRG |
| Exon 6 | PPARA, PPARD, PPARG, NR5A1, NR5A2, NR6A1, NR2F1, NR2F2, NR2F6, NR2C1, NR2C2 | |
| Exon 9 | NR1D1, NR1H2, NR1H3, ESR1, ESR2, THRA, THRB |